CLINICAL & PIPELINE·Drug Approval
Sanofi Aventis US Secures Latest FDA Labeling Approval for AUBAGIO (Teriflunomide)
Sanofi Aventis US recently secured FDA approval for a supplemental labeling update (SUPPL 18) for its oral drug, AUBAGIO (teriflunomide), on February 11, 2026. This marks another step in the product's lifecycle management since its original New Molecular Entity approval in 2012, impacting regulatory compliance and commercial strategy for procurement and supply chain leaders.
90-Day Activity